Dark Blue Therapeutics is an innovative cancer drug discovery company leveraging ground-breaking therapeutic and disease insights to exploit cancer’s vulnerabilities and dependencies.
Learn more about our scienceWe combine proprietary chemical and functional genomics with deep insights from our academic partners to identify drug targets with high translational potential. This is coupled with an industry-leading structurally enabled medicinal chemistry platform to deliver transformational precision medicines for molecularly defined high unmet need patient populations.
See our portfolioAt Dark Blue Therapeutics we believe the challenges of cancer drug discovery require a fully committed collaborative approach to succeed. We are deeply embedded in the Oxford University ecosystem and partner closely with world leading academics in Oxford and beyond to leverage deep target and mechanistic insights.
Our extensive partner network enables us to work across a wide range of cancer biology. Using these unique insights, we can prosecute challenging targets with the optimal drug mechanism to deliver transformative medicines.
Unique insights drive differentiated and transformational approaches
Relentless emphasis on therapeutic hypothesis and highly optimized medicines
Clear line of sight to address unmet need in molecularly defined patient populations
Pipeline of
high value
first-in-class drugs with transformational potential.
Unique insights drive differentiated and transformational approaches
Relentless emphasis on therapeutic hypothesis and highly optimized medicines
Clear line of sight to address unmet need in molecularly defined patient populations
Pipeline of
high value
first-in-class drugs with transformational potential.